Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 439, 391 (26 January 2006) | doi:10.1038/439391a; Published online 25 January 2006
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Professor of Experimental Virology (W3)
- University Hospital Jena, Institute of Virology and Antivirale Therapy
- Jena, Germany
Tenure-track Faculty Positions
- University of Michigan
- Ann Arbor, Michigan, USA
In brief
The US Food and Drug Administration last week agreed that potential flu drug peramivir can be fast-tracked through the approval process. Made by BioCryst Pharmaceuticals of Birmingham, Alabama, peramivir is an injectable drug that may be able to treat avian flu.
To read this story in full you will need to login or make a payment (see right).
